Olaparib

descriptionPublicationkeyboard_double_arrow_right Article 24 Oct 2015 English Publisher:WileyJournal:British Journal of Clinical Pharmacology, volume 81, pages 171-173 (issn: 0306-5251, eissn: 1365-2125,

Copyright policy )

Authors: S C, Goulooze; A F, Cohen; R, Rissmann;

doi: 10.1111/bcp.12761

pmid: 26344419

pmc: PMC4693566

Olaparib

- Summary
- Subjects
- Metrics

Abstract

Olaparib is used to treat BReast CAncer susceptibility protein (BRCA)‐associated, platinum‐sensitive ovarian cancer. Olaparib inhibits poly(ADP‐ribose) polymerase, thereby blocking the repair of single‐strand DNA breaks. This results in synthetic lethality in BRCA‐associated cancer cells, which have a dysfunction of another DNA repair pathway – homologous recombination.

Related Organizations

Leiden University Medical Center
Netherlands
Centre for Human Drug Research
Netherlands

Keywords

DNA Repair, Neoplasms, Humans, Phthalazines, Antineoplastic Agents, Poly(ADP-ribose) Polymerase Inhibitors, Piperazines

Impact byBIP!

	selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	26
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Top 10%
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Top 10%
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Average